These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

906 related items for PubMed ID: 24891437

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD, FIND-CKD Study investigators.
    BMC Nephrol; 2017 Jan 17; 18(1):24. PubMed ID: 28095881
    [Abstract] [Full Text] [Related]

  • 4. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
    Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC, FIND-CKD Study Investigators.
    Nephrol Dial Transplant; 2017 Sep 01; 32(9):1530-1539. PubMed ID: 28339831
    [Abstract] [Full Text] [Related]

  • 5. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
    Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC.
    PLoS One; 2016 Sep 01; 11(6):e0157063. PubMed ID: 27276035
    [Abstract] [Full Text] [Related]

  • 6. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A, Mircescu G.
    Nephrol Dial Transplant; 2010 Aug 01; 25(8):2722-30. PubMed ID: 20190247
    [Abstract] [Full Text] [Related]

  • 7. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
    Nephrol Dial Transplant; 2013 Apr 01; 28(4):953-64. PubMed ID: 23222534
    [Abstract] [Full Text] [Related]

  • 8. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol; 2014 Jun 01; 81(6):419-26. PubMed ID: 24691014
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
    Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD.
    Nephrol Dial Transplant; 2011 May 01; 26(5):1599-607. PubMed ID: 20929915
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE, Di Gennaro F.
    PLoS One; 2015 May 01; 10(4):e0125528. PubMed ID: 25928811
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
    Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.
    Ann Oncol; 2013 Feb 28; 24(2):475-482. PubMed ID: 23071262
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Feb 28; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T, Bedouch P, Zaoui P.
    Nephrol Ther; 2019 Apr 28; 15(2):104-109. PubMed ID: 30803900
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.